PT-141 Dosage Guide: Injection and Nasal Protocols
The 1.75 mg Vyleesi autoinjector has specific product instructions. Research vials and nasal sprays do not inherit them. This guide separates approved use, early research, reported experience and arithmetic so that a dose calculation is not mistaken for a treatment recommendation. For background on the molecule itself, see the main PT-141 peptide overview.
PT-141 Dosage Chart: Quick Reference
This chart separates the approved product from research formulations. It is not a menu of interchangeable doses. Early study amounts describe those studies, not a self-treatment schedule.
| Product or evidence | Amount and route | Timing and limits | What it establishes |
|---|---|---|---|
| Vyleesi autoinjector | Fixed 1.75 mg/0.3 mL, subcutaneous | At least 45 minutes before activity; no more than one dose within 24 hours; more than eight per month not recommended | Approved instructions for eligible premenopausal women with acquired, generalized HSDD |
| Vialed preparations | No universal concentration or starter dose | Exact prescription and pharmacy directions required | The brand label does not validate a research vial or compounded formulation |
| Early intranasal research | Study-specific nasal formulations; not an injection-dose conversion | No Vyleesi-approved nasal schedule | Positive early erectile-response signals, not a validated community spray regimen |
Sources: Vyleesi prescribing information; Diamond and colleagues: early intranasal study.
The FDA-Approved Dose: Vyleesi at 1.75 mg
Vyleesi is approved for acquired, generalized HSDD in premenopausal women when low desire is not explained by a medical or psychiatric condition, relationship problems or medication effects. Each single-use autoinjector delivers 1.75 mg in 0.3 mL into the abdomen or thigh, at least 45 minutes before anticipated sexual activity. It is fixed-dose, not a pen to dial down or titrate.
Do not administer more than one dose within 24 hours. More than eight doses per month is not recommended, because more frequent exposure increases pigmentation risk and time with elevated blood pressure. The label advises discontinuation after eight weeks without improvement. These are product instructions, not a goal to use eight doses. Vyleesi prescribing information, sections 1–3.
Research Subcutaneous Dosing
Research and clinician experience should be distinguished from approved-product instructions. A lower test dose that someone reports using is anecdotal information, not a validated 0.5-to-1 mg starter regimen. Similarly, tolerating a first dose does not establish that escalating or using it more frequently is appropriate.
Dose-finding studies preceded Vyleesi, so it would also be inaccurate to say no research ever examined other amounts. The selected 1.75 mg regimen applies to the studied product and population; it does not establish equivalence for self-mixed vials. Kingsberg and colleagues: RECONNECT trials.
Our how to inject BPC-157 guide is related background, not PT-141 preparation instructions. Injection devices, formulations and prescribed routes are not interchangeable simply because both products are described as peptides.
Nasal Spray Dosing
Early human evidence: a 2004 placebo-controlled intranasal study in healthy men and men with erectile dysfunction reported significant erectile responses at studied amounts above 7 mg, with generally favorable short-term tolerability. This is historical research, not a recommended dose. Diamond and colleagues: early intranasal study.
A separate 19-man study combined a study-specific 7.5 mg intranasal preparation with low-dose sildenafil and found an enhanced erectile response. It did not establish long-term combination safety or a self-directed spray regimen. Neither study validates an unsourced 1-to-2 mg community protocol, a particular commercial spray, or conversion from the 1.75 mg injection. Spray concentration and delivered volume are formulation-specific. 19-man crossover study.
Reconstitution: Turning a Vial into a Dose
Vyleesi needs no reconstitution. Its autoinjector is ready to use and delivers the labeled fixed dose. A different prescribed preparation needs its own pharmacy instructions for diluent, final volume, device, storage and discard time. Adding bacteriostatic water does not establish compatibility, sterility or a universal shelf life.
Arithmetic example only: if a verified preparation contains 10 mg in a final solution volume of 2 mL, the concentration is 10 ÷ 2 = 5 mg/mL. If the prescription separately specifies 1.75 mg, the calculated volume is 1.75 ÷ 5 = 0.35 mL, equal to 35 U-100 syringe markings. Those markings express volume, not biological units of PT-141. This example does not prescribe that preparation or amount, and is not a Vyleesi pen conversion.
The retained calculator is a general arithmetic tool. Its starting values, compound presets and frequency choices are not PT-141 recommendations. Enter only confirmed product and prescription values; the calculation cannot validate a safe treatment protocol.
Peptide Reconstitution Calculator
Calculate concentration and volume arithmetic from entered product values
Starting mass is an illustrative example. Replace it with the amount shown on the actual product label.
Enter the total volume after mixing, not the vial capacity. The starting mass and 2 mL volume are illustrative examples, not a prescribed regimen. The calculator does not select a diluent; use product-specific preparation instructions.
Optional arithmetic input; no amount is preselected. Results are calculated quantities, not dose recommendations.
Used only for theoretical arithmetic duration; it is not a treatment schedule or shelf-life calculation.
Enter peptide amount, final solution volume, and desired dose to see calculations
Disclaimer: This calculator is for research and educational purposes only. It is not medical advice. Always consult with a healthcare professional before using any peptide product. Verify all calculations independently.
Do not apply a generic "few weeks refrigerated" rule. Vyleesi and a pharmacy-prepared vial may have different handling requirements. Follow the exact label; our peptide storage guide explains why preparation-specific instructions matter. Vyleesi prescribing information.
Timing and Administration
Vyleesi is taken at least 45 minutes before anticipated activity. The optimal window and duration of benefit have not been fully characterized, so reports of a one-to-three-hour onset are individual experience rather than a guaranteed timetable. Do not take another dose within 24 hours to chase a delayed effect. Vyleesi prescribing information.
A symptom and timing record can help a prescriber assess whether treatment is useful. A light meal is not an established way to prevent Vyleesi nausea. Routine ondansetron pretreatment also did not reduce nausea incidence in the randomized study described in the current label; clinician-directed treatment of bothersome nausea is a separate decision.
Dosing in Men vs Women
The approved Vyleesi indication is specific to premenopausal women with acquired, generalized HSDD. It is not indicated for men or postmenopausal women, and there is no approved male dose. Vyleesi prescribing information.
Male use is not wholly unstudied: early intranasal trials found erectile-response signals. However, those formulations and research conditions do not establish that men should borrow the female injection dose or an online titration schedule. Off-label prescribing of an approved medicine is also different from using a research-only product. Diamond and colleagues: early intranasal study; 19-man crossover study.
Side Effects and Safety Limits
Nausea occurred in 40% of Vyleesi-treated participants in pivotal trials, and 8% stopped because of it. Flushing, headache and injection-site reactions were also common. Temporary blood-pressure increases and heart-rate reductions usually resolved within 12 hours; these trial findings do not guarantee the same response for every individual or preparation.
Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. More frequent use increases focal pigmentation risk; darkening can persist. The prescriber should assess cardiovascular risk and the exact formulation, not just whether a lower dose seems tolerable.
The label also warns about altered oral-drug absorption and avoiding oral naltrexone-containing products used for alcohol or opioid addiction. Use effective contraception and stop Vyleesi if pregnancy is suspected. These are not all potential issues; review current medicines and relevant conditions with the clinician. Vyleesi prescribing information.
Common Dosing Mistakes
Common errors include treating a fixed-dose pen as adjustable, confusing mg with mL or syringe markings, assuming a nasal spray matches an injection, redosing within 24 hours, and transferring one product's storage rule to another. A mathematically correct result does not resolve those problems.
Different receptor targets or separate injection sites do not establish that a PT-141/BPC-157/GH-peptide combination is safe. No validated stacking protocol is supplied here. Ask the prescriber to review every component, and do not mix products in a syringe or improvise dose changes from a general calculator.
Frequently Asked Questions About PT-141
Vyleesi delivers a fixed 1.75 mg in 0.3 mL by single-use subcutaneous autoinjector into the abdomen or thigh, at least 45 minutes before activity, for its approved HSDD population. It is not an adjustable starter-dose pen. This does not establish a universal dose for research vials, compounded products, nasal sprays or men.
The Vyleesi label specifies at least 45 minutes before anticipated activity. The optimal window and duration of benefit are not fully characterized. Individual timing reports are not guarantees, and a delayed effect is not a reason to take another dose within 24 hours.
Vyleesi is used on demand. Do not administer more than one dose within 24 hours; more than eight doses per month is not recommended. Eight is not a target frequency, and a daily preventive regimen is not established by the label. Stop after eight weeks without symptom improvement as directed in the prescribing information.
There is no Vyleesi-approved nasal dose. Early male trials tested specific intranasal formulations and found erectile-response signals, but did not validate a universal community spray schedule. The injection dose cannot simply be converted to a number of sprays.
Vyleesi is approved for acquired, generalized HSDD in premenopausal women, not for men or postmenopausal women. Early male studies exist, but do not establish an approved male dose or justify automatically borrowing the female injection regimen.
Vyleesi is ready to use and needs no reconstitution. A different prescribed preparation requires exact pharmacy instructions for diluent, final volume, concentration, device, storage and discard time. The calculator checks arithmetic only; it cannot establish compatibility, sterility or an appropriate treatment dose.
Nausea, flushing, headache and injection-site reactions are common with Vyleesi. Blood pressure can temporarily rise while heart rate falls, and focal pigmentation can persist. Higher or more frequent exposure can increase risks. Uncontrolled hypertension or known cardiovascular disease are contraindications; a smaller dose is not a workaround.
Different mechanisms do not establish combination safety. Separate injection sites do not validate a PT-141/BPC-157/GH-peptide stack or remove systemic interactions. Review every component with the prescriber, including medicines whose oral absorption may be affected, and do not mix products in a syringe or use a general calculator as a stacking protocol.